Ahmedabad, Gujarat, India, January 2026 – Raviraj Karia has assumed the role of Chief Financial Officer at Concord Biotech Limited, a globally recognized R&D-driven biotechnology organization specializing in fermentation-based APIs and enzymes. In this strategic position, he will partner with the CEO to shape long-term growth, lead mergers and acquisitions, strengthen investor relations, and drive digital transformation across finance and supply chain functions.
Prior to joining Concord Biotech Limited, Raviraj Karia served as Senior Vice President at Sakar Healthcare for a brief tenure in 2025, where he handled multi-dimensional responsibilities spanning finance, commercial operations, supply chain, and IT. He played a key role in strengthening financial performance, treasury management, compliance frameworks, and stakeholder engagement while supporting acquisition strategy and profitability initiatives.
Before this, Raviraj spent nearly a decade at Intas Pharmaceuticals as Global Lead – Internal Audit and Lead – Mergers & Acquisitions, a period that defined his global exposure and strategic depth. He led large cross-border audits across the USA, UK, Europe, and Asia, managed engagements with boards and private equity stakeholders, and was instrumental in landmark transactions including the acquisition of the Teva/Actavis entity—one of India’s largest outbound deals valued at GBP 600 million. He also structured over USD 3 billion in borrowings and USD 0.8 billion in equity raises, while actively driving in-licensing, CDMO, and portfolio negotiations.
Earlier in his career, he was Lead Commercial – Finance & Procurement at Lambda Therapeutic Research, where he headed finance, treasury, and IPO readiness while implementing full automation of procurement. As Vice President – Finance at Shalby Limited, he architected long-term funding strategies, credit ratings, and acquisition-led expansion that helped scale the organization from a 200-bed to a 2000-bed hospital network. His tenure at Gati Limited (Allcargo Group) as Head of Finance – Commercial saw him lead turnaround strategy, private equity investment processes, and divestment initiatives.
Raviraj began building his strong M&A and treasury expertise at Intas Pharmaceuticals as AGM–Finance, where he managed IPO processes, PE investments, ECB financing, and global acquisitions with a borrowing portfolio exceeding INR 1100 crore. His early professional years at GVFL and Claris Lifesciences provided a strong foundation in venture investing, financial modeling, and corporate governance.
Concord Biotech Limited is a research-driven biotechnology company focused on fermentation, semi-synthetic, and synthesis-based products. Established in 2000, the company operates state-of-the-art US FDA and EUGMP-approved facilities and is a global supplier of APIs in immunosuppressant, antibiotic, oncology, anti-obesity, and hypolipemic segments. Concord also offers specialized biotechnology services including strain improvement and contract manufacturing, and continues to expand its portfolio through cutting-edge R&D.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
